Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334068 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL3329351 | 0.91 | KDM4E (0.35) | KDM4EMAPTCYP1A2CYP2D6KIF11 | |
| SCHEMBL3329349 | 0.91 | KDM4E (0.35) | KDM4EMAPTCYP1A2CYP2D6KIF11 | |
| SCHEMBL3329991 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3332677 | 0.87 | KIF11 (0.37) | KDM4EKIF11 | |
| SCHEMBL3332133 | 0.87 | KIF11 (0.38) | KDM4EALDH1A1KIF11 | |
| SCHEMBL3330371 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3329995 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3331631 | 0.84 | HPGD (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3331635 | 0.84 | HPGD (0.33) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344154-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | KDM4E 3386/4885ALDH1A1 1218/4885MAPT 3619/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | KDM4E 2518/4885ALDH1A1 1182/4885MAPT 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.